- Published at
- by manilatimes.net
positive
positive
News for BioStem Technologies, Inc. (BSEM)
- Published at
- by gurufocus.com
positivepositiveBioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
Study comparing BioStem's proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinic- Published at
- by investing.com
positivepositiveBioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million By Investing.com
BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million- Published at
- by gurufocus.com
positivepositiveBioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million
POMPANO BEACH, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ( BSEM) (”BioStem”, ”we”, ”us”, or ”our”), a leading MedTech- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveBioStem Technologies CEO to Present at Biotech Showcase 2025
Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ( BSE- Published at
- by gurufocus.com
mixedmixedKane Biotech Announces Third Quarter 2024 Financial Results
Company Records First Commercial Sale of revyveâ„¢ Wound GelWINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF)- Published at
- by gurufocus.com
mixedmixedKane Biotech Announces Third Quarter 2024 Financial Results
Company Records First Commercial Sale of revyveâ„¢ Wound Gel WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; KNBIF) (”- Published at
- by manilatimes.net
mixedmixed- Published at
- by financialpost.com
neutralneutralKane Biotech Announces Third Quarter 2024 Financial Results
Company Records First Commercial Sale of revyve™ Wound Gel- Published at
- by gurufocus.com
positivepositiveKane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyveâ„¢ from ProgenaCare Global WINNIPEG, Manitoba, Nov. 27, 20- Published at
- by manilatimes.net
positivepositive- Published at
- by globenewswire.com
positivepositiveBioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment...- Published at
- by seekingalpha.com
positivepositiveBioStem Technologies: A New Growth Star In Health Care (OTCMKTS:BSEM)
BioStem has enjoyed exceptional growth in its first year as a public company, with revenues soaring. Read why I think BSEM stock is a strong buy.